ViAqua

Categories
Founded

2014

Leadership
  • Shai Ufaz, PhD, Co-Founder and CEO
Headquarters

Haifa, Israel

Website

viaqua-t.com

S2G North Star Interim Outcomes Jump to footnote 1
  • Increased demand for healthier and sustainable seafood
  • Increased uptake of solutions, products, and technologies that enhance productivity of blue economy
UN SDG Alignment Jump to footnote 2
  • Zero Hunger
  • Good Health and Well-Being
  • Life Below Water
ViAqua is a developer of an RNA-particle platform to promote and improve animal health in aquaculture.

The company was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. ViAqua’s biotechnology-based, oral delivery platform is intended for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA-based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.

Insights

News

Footnotes

  1. S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.

  2. UN Sustainable Development Goal (SDG) alignment has been obtained from portfolio companies, internally collected data by S2G and/​or sources outside S2G, and could prove to be incomplete or inaccurate and is current only as of July 31, 2026. S2G makes no representations as to the accuracy or completeness of the information obtained from such portfolio companies and/​or sources and neither S2G nor any of its affiliates takes any responsibility for, and has not independently verified, any such information.